MedWatch

Snipr Biome and US cancer hospital target gut microbes in attempt to eradicate immune therapy side effects

The preclinical collaboration with the US cancer hospital MD Anderson could prove crucial for the biotech company when it raises capital in 2022.

Photo: EY / PR

At Snipr Biome, preparations to break out of its mold have begun.

Even though the company's main focus has been developing treatments for difficult-to-treat infections, Snipr is now setting its sights on an entirely new area by partnering with the prestigious Texan cancer hospital MD Anderson. Snipr is now going to help the improve side effects of immune therapy.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs